Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SPECTRUM PHARMACEUTICALS, INC.

(SPPI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Spectrum Pharmaceuticals : Letter from Deloitte & Touche LLP addressed to the Securities Exchange Commission, dated June 2, 2021 (Form 8-K)

06/02/2021 | 04:29pm EST


June 2, 2021
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561

Dear Sirs/Madams:
We have read Item 4.01 of Spectrum Pharmaceuticals, Inc.'s Form 8-K dated June 2, 2021, and have the following comments:
1. We agree with the statements made in the second, third, and fourth paragraphs of 4.01(a).
2. We have no basis on which to agree or disagree with the statements made in the first paragraph of 4.01(a), and 4.01(b).
Yours truly,
/s/ Deloitte & Touche LLP


Disclaimer

Spectrum Pharmaceuticals Inc. published this content on 02 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 June 2021 20:28:01 UTC.


ę Publicnow 2021
All news about SPECTRUM PHARMACEUTICALS, INC.
12/01Spectrum Pharmaceuticals CEO Agrees to Retire, COO Named Successor From Dec. 31
MT
12/01Spectrum Pharmaceuticals Announces Changes to Management Team and Board of Directors
BU
11/30Spectrum Pharmaceuticals to Participate in JMP Securities Hematology and Oncology Summi..
BU
11/11Spectrum Pharmaceuticals to Participate in 2021 Jefferies London Healthcare Conference
BU
11/10Spectrum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Upd..
PU
11/10Spectrum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine ..
CI
11/10SPECTRUM PHARMA : Q3 Earnings Snapshot
AQ
11/10Spectrum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Upd..
BU
11/03Spectrum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Provide Cor..
BU
11/03SHAREHOLDER ALERT : Robbins LLP Investigates Spectrum Pharmaceuticals, Inc. (SPPI) for Mis..
BU
More news
Analyst Recommendations on SPECTRUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -152 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,72x
Yield 2021 -
Capitalization 268 M 268 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 8,33x
Nbr of Employees 176
Free-Float 98,5%
Chart SPECTRUM PHARMACEUTICALS, INC.
Duration : Period :
Spectrum Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPECTRUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 1,68 $
Average target price 5,75 $
Spread / Average Target 242%
EPS Revisions
Managers and Directors
Joseph W. Turgeon President, Chief Executive Officer & Director
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
William L. Ashton Chairman
Francois Lebel Chief Medical Officer
Lyndah K. Dreiling Senior Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
SPECTRUM PHARMACEUTICALS, INC.-50.73%268
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-41.09%24 625